Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-03-21 Annual Report (ESEF)
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Document d'enregistrement universel 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-03-21 French
bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance
Regulatory Filings Classification · 95% confidence The document is a press release dated March 18, 2025, announcing that bioMérieux received FDA 510(k) clearance for its VITEK® COMPACT PRO system. This type of announcement, detailing a specific regulatory achievement (FDA clearance) and its implications for product launch and market strategy, is typically classified as a general corporate announcement or news release. It is not a comprehensive financial report (10-K, IR), a management discussion (MDA), an earnings release (ER), or a specific shareholder communication (DEF 14A, DIV). Since it is a specific, non-financial regulatory/product update that doesn't fit the other specific categories (like M&A, Capital Change, or Director Dealing), the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a catch-all for significant corporate news that isn't strictly financial reporting or a formal statutory filing like a 10-K or proxy statement. The document length (6906 chars) is substantial enough that it is the primary content, not just an announcement of another document (ruling out RPA).
2025-03-18 English
bioMérieux obtient l’autorisation 510(k) de la FDA pour VITEK® COMPACT PRO, un nouveau système d’identification et d’antibiogramme permettant de lutter contre l’antibiorésistance
Regulatory Filings Classification · 100% confidence The document is a press release dated March 18, 2025, announcing that bioMérieux has received 510(k) clearance from the US FDA for its VITEK® COMPACT PRO system. It details the product's features, benefits in fighting antimicrobial resistance, and provides quotes from executives. This type of announcement, focusing on a specific regulatory milestone (FDA clearance) and product launch/update, is typically classified as a general corporate announcement or news release. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a management change (MANG), the most appropriate category is the general regulatory/news filing fallback, RNS (Regulatory Filings), as it communicates a significant operational/regulatory event to the market, although it shares characteristics with an Earnings Release (ER) in terms of being a timely announcement. Given the focus is on regulatory clearance and product news rather than period financial results, RNS is the best fit among the provided options, as it serves as a general regulatory announcement.
2025-03-18 French
AG 2025 - Avis de mise à disposition des documents préparatoires
AGM Information Classification · 98% confidence The document is titled "Avis de mise à disposition des documents relatifs à L'Assemblée générale mixte du 15 mai 2025" (Notice of availability of documents relating to the Combined General Meeting of May 15, 2025). It explicitly announces the upcoming Annual General Meeting (AGM) and details how shareholders can access the related documents (resolutions, agenda, etc.). This is a formal announcement regarding the AGM materials, not the AGM presentation itself, nor is it a proxy statement (PSI) or a declaration of voting results (DVA). Since it is a specific announcement about the availability of AGM-related documents, the most appropriate classification is AGM Information (AGM-R), as it directly pertains to the AGM event and its preparation materials.
2025-03-14 French
bioMérieux – 2024 Financial Results
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – 2024 Financial Results" and contains detailed consolidated financial data for the full year ending December 31, 2024, including Net Sales, Contributive operating income, Net income, and segment breakdowns. It explicitly mentions the approval of 'audited consolidated financial statements for the year ending December 31, 2024' by the Board of Directors on March 6, 2025. The content is a comprehensive review of annual performance, which aligns perfectly with the definition of an Annual Report (10-K), although this specific document might be the press release version accompanying the 10-K filing. Given the depth of financial figures, segment analysis, and the reference to the full year's audited results, it is classified as the primary Annual Report document type (10-K), rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). The length (over 58,000 characters) also supports this being a substantive report. FY 2024
2025-03-07 English
bioMérieux – Résultats annuels au 31 décembre 2024
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Résultats annuels au 31 décembre 2024" (Annual Results as of December 31, 2024). It contains detailed financial figures for the full year 2024, including consolidated accounts, revenue breakdowns by application and region, operating income (ROCC), net income, and forward-looking guidance for 2025. The text explicitly mentions the Board of Directors approved the 'comptes consolidés audités du Groupe au 31 décembre 2024' (audited consolidated accounts of the Group as of December 31, 2024). This structure and content strongly indicate a comprehensive annual financial report, which corresponds to the definition of a 10-K (Annual Report), even though the document is in French and might be a local equivalent or a press release accompanying the official filing. Given the depth of the audited annual figures, 10-K is the most appropriate classification among the provided options for a full-year financial report. FY 2024
2025-03-07 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.